503111-98-6

Basic information

• Product Name: (1S, 2S)-1,2-Bis(4-fluorophenyl)-1,2-ethanediamine dihydrochloride
• Synonyms: (1S, 2S)-1,2-Bis(4-fluorophenyl)-1,2-ethanediamine dihydrochloride;(1S, 2S)-1,2-Bis(4-fluorophenyl)ethylenediamine dihydrochloride
• CAS NO: 503111-98-6
• Molecular Formula: C₁₄H₁₄F₂N₂
• Molecular Weight: 248.27
• Mol File: 503111-98-6.mol

Chemical Properties

• Melting Point: 247-251 °C
• Boiling Point: 356.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.239±0.06 g/cm3(Predicted)
• PKA: 9.62±0.10(Predicted)
• CAS DataBase Reference: (1S, 2S)-1,2-Bis(4-fluorophenyl)-1,2-ethanediamine dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (1S, 2S)-1,2-Bis(4-fluorophenyl)-1,2-ethanediamine dihydrochloride(503111-98-6)
• EPA Substance Registry System: (1S, 2S)-1,2-Bis(4-fluorophenyl)-1,2-ethanediamine dihydrochloride(503111-98-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 503111-98-6(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry and Pharmaceutical Research:
(1S, 2S)-1,2-Bis(4-fluorophenyl)-1,2-ethanediamine dihydrochloride serves as a valuable building block for the synthesis of chiral ligands and catalysts, which are essential in various chemical reactions and drug development processes. Its unique structure and properties make it a promising candidate for creating new and improved pharmaceutical agents.
Used as a Reagent in Asymmetric Synthesis:
In the field of organic chemistry, (1S, 2S)-1,2-Bis(4-fluorophenyl)-1,2-ethanediamine dihydrochloride is employed as a reagent in asymmetric synthesis. This process is crucial for producing enantiomerically pure compounds, which are important in the development of drugs with specific biological activities and reduced side effects.
Used in the Development of Therapeutic Agents:
(1S, 2S)-1,2-Bis(4-fluorophenyl)-1,2-ethanediamine dihydrochloride has demonstrated potential as a therapeutic agent for the treatment of certain diseases. Its unique structure and properties allow it to interact with biological targets in ways that could lead to the development of new treatments and therapies.
Overall, (1S, 2S)-1,2-Bis(4-fluorophenyl)-1,2-ethanediamine dihydrochloride is a versatile chemical compound with a range of potential applications in the fields of science and medicine, making it an important asset for researchers and pharmaceutical companies alike.

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 1267688-18-5 (R)-N-(4-fluorobenzylidene)-2-methylpropane-2-sulfinamide 
• 160313-82-6 N-trimethylsilyl-4-fluorobenzaldimine 

Relevant articles and documents

Synthesis and cytotoxic evaluation of novel platinum(II) complexes with C2-asymmetric and C2-symmetric chiral vicinal diamines

A series of new platinum(II) complexes with C2-asymmetric and C2-symmetric 1,2-diamines were designed and synthesized by convenient methods, involving samarium diiodide induced reductive coupling as the key step. The results of cytotoxicity showed that compounds (R,R)-11a and (S,S)-11a, two novel platinum(II) complexes with asymmetric 1,2-diamines, exhibited more potent cytotoxicity than that of oxaliplatin against all leukemia cell lines. Interestingly, (R,R)-11a and (S,S)-11a demonstrated less potent activity against three solid cancer cell lines than that of oxaliplatin, which indicated that these two compounds may only selectively inhibit the leukemia cell lines. In contrast, (R,R)-15a and (S,S)-15a, two platinum(II) complexes with symmetric 1,2-diamines, showed similar cytotoxicity to that of oxaliplatin against all leukemia cell lines and more potent activity against solid cancer cell lines. Further flow cytometry data indicated that (R,R)-11a could obviously arrest leukemia K562 cells in G2/M phases. A series of new platinum(II) complexes with C2-asymmetric and C2-symmetric 1,2-diamines were designed and synthesized by convenient methods, involving samarium diiodide induced reductive coupling as the key step. The cytotoxicity of these analogs against four leukemia and three solid cancer cell lines was evaluated and the preliminary structure-activity relationship is also discussed. Flow cytometry data indicated that (R,R)-11a could obviously arrest leukemia K562 cells in G2/M phases. Copyright

Electronic Control of Chiral Quaternary Center Creation in the Intramolecular Asymmetric Heck Reaction

The Boehringer-Ingelheim phosphinoimidazoline (BIPI) ligands were applied to the formation of chiral quaternary centers in the asymmetric Heck reaction. Several different substrates were examined in detail using more than 70 members of this new ligand class. Hammett relationships were determined through systematic variation of the ligand electronics. All substrates showed essentially the same Hammett behavior, where enantioselectivity increased as the ligands were made more electron-deficient. Ligand optimization has led to catalysts which give the highest enantioselectivities reported to date for these difficult systems.